Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ardelyx Inc (NQ: ARDX )

5.690 +0.340 (+6.36%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ardelyx Inc

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Ardelyx Inc. (NASDAQ: ARDX) is a Stock Spotlight on 8/30
Via Investor Brand Network
3 Penny Stocks You’ll Regret Not Buying Soon
There are plenty of penny stocks to buy, but not all of them are created equal. Here are some of the best options to choose from. 
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For August 25, 2023
Via Benzinga
Hibbett, American Software, Ardelyx And Other Big Stocks Moving Higher On Friday
U.S. stocks traded higher, with the Dow Jones gaining over 100 points on Friday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
Exposures US Equities
Earnings Outlook For Ardelyx
Via Benzinga
Recap: Ardelyx Q1 Earnings
Via Benzinga
Earnings Preview For Ardelyx
Via Benzinga
Ardelyx Inc. (NASDAQ: ARDX) is a Stock Spotlight on 4/18
Via Investor Brand Network
Don’t Sleep on These 3 Penny Stocks That Will Mint Millionaires
These top three penny stocks are the ones to buy that will mint your investment status to a millionaire in returns. 
Via InvestorPlace
5 Meme Stocks to Sell Immediately, According to AI
As we move into September, the MarketMaster AI is flashing warning signals about risky equities. Sell these meme stocks right now. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
3 Cheap Biotech Stocks That Smart Investors Will Snap Up Now
One of the safest sectors on the market is biotech. Here are three cheap biotech stocks to buy that are good options for investors. 
Via InvestorPlace
Ardelyx Reports Second Quarter 2023 Financial Results and Provides 2023 IBSRELA Net Sales Revenue Guidance
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx, Inc. Reports Employment Inducement Grants
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx to Report Second Quarter 2023 Financial Results on August 2, 2023
Conference call scheduled for 8:00 a.m. Eastern Time 
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx to Present at the H.C. Wainwright 2nd Annual Kidney Conference
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx Announces Acceptance of New Drug Application for Tenapanor for Hyperphosphatemia in China
Acceptance of NDA Submission triggers as $2 million milestone payment to Ardelyx by Fosun Pharma 
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx, Inc. Reports Employment Inducement Grants
From Ardelyx, Inc.
Via GlobeNewswire
Leading Proxy Advisory Firms ISS and Glass Lewis Recommend Ardelyx Stockholders Vote in Favor of Proposed Share Increase
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx to Present at the Jefferies 2023 Healthcare Conference
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx, Inc. Reports Employment Inducement Grants
From Ardelyx, Inc.
Via GlobeNewswire
Why Doximity Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers 
Via Benzinga
Ardelyx Announces FDA Acceptance and Six-Month Review for Resubmission of its New Drug Application of XPHOZAH® (tenapanor)
User Fee Goal Date: October 17, 2023 
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx, Inc. Reports Employment Inducement Grants
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx Presents Positive Data at DDW 2023 on IBSRELA® (tenapanor), a First-In-Class Treatment for IBS-C in Adults
From Ardelyx, Inc.
Via GlobeNewswire
7 High-Potential Penny Stocks in the Biotech Sector
Most of the biggest biotech stocks on the market started off as unknown penny stocks. Here are seven hot ones to consider. 
Via InvestorPlace
Ardelyx Reports First Quarter 2023 Financial Results and Provides Business Update
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx Announces Additional Data Supporting First-In-Class IBSRELA® (tenapanor) for Adults with IBS-C, to be Presented at the 2023 Digestive Disease Week Conference
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx to Report First Quarter 2023 Financial Results and Provide Business Update on May 3, 2023
Conference call scheduled for 4:30 p.m. Eastern Time 
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx Resubmits New Drug Application to U.S. Food and Drug Administration for XPHOZAH® (tenapanor)
Company expects to receive goal review date in mid-May 
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx, Inc. Reports Employment Inducement Grants
From Ardelyx, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.